Shufeng Xingbi Therapy Restores Th1/Th2 Balance and Gut Flora in AR Rats

Study Background and Research Question

Allergic rhinitis (AR) is a prevalent, chronic inflammatory disease of the nasal mucosa, characterized by paroxysmal sneezing, watery discharge, nasal itching, and congestion. Globally, AR affects over 10% of the population and is rising in incidence, significantly impacting patient quality of life and healthcare resources. Central to AR pathology is an imbalance between Th1 and Th2 immune responses, typically skewed towards Th2 dominance, resulting in excessive IgE-mediated reactions upon allergen exposure (reference study). Growing evidence links the intestinal microbiota with immune regulation in allergic diseases, supporting the 'hygiene hypothesis' which posits that environmental and microbial exposures modulate immune maturation and subsequent allergy risk. Short-chain fatty acids (SCFAs), produced by gut bacteria, are recognized as key mediators in immune signaling and inflammation. However, standard AR treatments—including glucocorticoids and antihistamines—may induce side effects, especially in pediatric populations, and their long-term influence on mucosal immunity and the microbiome remains unclear. Shufeng Xingbi Therapy (SFXBT), a traditional Chinese medicinal approach, integrates oral herbal administration with topical nasal application. While SFXBT is used clinically for AR, its mechanistic impact on the Th1/Th2 axis and gut flora required detailed elucidation.

Key Innovation from the Reference Study

The reference study delivers a dual-omics and immunological perspective by simultaneously examining SFXBT's effects on both systemic immune balance and the composition of intestinal microbiota in an OVA-induced rat model of AR. This combined approach establishes a mechanistic framework for understanding how traditional therapies may simultaneously target immune and microbial networks, an area of growing relevance in allergy research.

Methods and Experimental Design Insights

The investigators randomized 32 male Sprague-Dawley rats into four groups: control, OVA (ovalbumin-induced AR model), antibiotic + SFXBT, and acetic acid + SFXBT. This design allowed for the assessment of SFXBT alone and in the context of disturbed microbiota. Key methodological elements include:

• Behavioral assessment: AR symptom scoring to quantify sneezing and nasal discharge.
• Histopathology: Hematoxylin-eosin (H&E) staining evaluated nasal mucosal inflammation severity.
• Microbiota profiling: 16S rDNA sequencing characterized colonic bacterial composition at phylum and genus levels.
• Immunological assays: Serum IgE, interleukin-4 (IL-4), and SCFA concentrations measured by ELISA.
• Gene and protein expression: RT-qPCR and Western blotting quantified STAT5, STAT6, and GATA3 mRNA and protein levels in nasal tissue, key markers of Th2 polarization.

Notably, the inclusion of antibiotic and acetic acid pretreatments enabled evaluation of how microbiota perturbation influences SFXBT's efficacy, highlighting the gut-immune axis.

Protocol Parameters

• OVA-induced AR modeling: Sensitize and challenge rats with ovalbumin to induce consistent AR pathology.
• Antibiotic pretreatment: Administer broad-spectrum antibiotics prior to SFXBT to model microbiota depletion effects.
• SFXBT administration: Combine oral Shufeng Xingbi recipe with topical Xingbi gel nasal drops, following dosing validated in prior clinical and preclinical studies.
• 16S rDNA sequencing: Collect colonic content after final treatment for microbial community analysis.
• Immunoassays and molecular analyses: Standardize serum and tissue sampling times post-intervention to ensure comparability.

Core Findings and Why They Matter

SFXBT markedly reduced AR behavioral scores and nasal mucosal inflammation compared to the OVA-only group. Immunologically, SFXBT led to significant reductions in serum IgE and IL-4 levels, indicating a shift away from Th2-skewed responses. Molecular analysis revealed downregulation of STAT5, STAT6, and GATA3, further supporting Th1/Th2 rebalancing. Microbiota analysis demonstrated a striking increase in Firmicutes and a decrease in Bacteroidetes at the phylum level. At the genus level, beneficial taxa such as Lactobacillus, Romboutsia, Allobaculum, and Dubosiella were enriched following SFXBT. Notably, colonic SCFA concentrations were elevated, which are known to exert anti-inflammatory effects and modulate immune cell function. These results suggest that SFXBT's efficacy in AR is mediated by restoration of gut microbial balance and enhancement of microbiota-derived metabolites, which in turn support immune homeostasis. The study provides experimental backing for clinical observations of SFXBT's benefit in allergic conditions.

Comparison with Existing Internal Articles

Recent internal articles such as "Shufeng Xingbi Therapy Modulates Immunity and Gut Flora in AR Rats" and "Shufeng Xingbi Therapy Modulates Th1/Th2 Balance & Gut Flora in AR Rats" corroborate these findings, emphasizing SFXBT's dual immunomodulatory and microbiota-altering actions. Both highlight the increase of SCFAs and beneficial bacterial genera as pivotal to SFXBT's mechanism, aligning with the present study's data. These articles also discuss the potential translation of such approaches to personalized allergy management, reinforcing the relevance of targeting both immune and microbial pathways. Moreover, research on microbiota-immune crosstalk has leveraged antibiotics such as Metronidazole in experimental models to perturb microbial communities and investigate downstream immune effects, as discussed in internal resources like "Metronidazole in Immune-Microbiota Research: Beyond OAT3". These studies provide methodological context for integrating microbiota-targeting agents into immunological research protocols.

Limitations and Transferability

While the study robustly demonstrates SFXBT's effects in a controlled rat model, several limitations merit consideration. The study's reliance on animal data precludes direct clinical extrapolation; human microbiota complexity and immune variability require cautious interpretation. Additionally, the precise herbal constituents driving observed effects were not dissected individually, and the duration of SFXBT exposure may differ from clinical practice. Transferability to other allergic or immune-mediated diseases remains to be determined, as does the impact of long-term or repeated SFXBT administration. Future studies should address dose optimization, duration, and the identification of active compounds within SFXBT.

Why this cross-domain matters, maturity, and limitations

The integration of immunological and microbiota endpoints reflects an emerging paradigm in allergy and inflammation research. By linking gut flora composition, SCFA metabolites, and Th1/Th2 modulation, the study exemplifies the cross-domain approach essential for unraveling complex host-microbe-immune interactions. Nonetheless, this maturity is currently limited to preclinical models, with translational research needed to establish efficacy, safety, and mechanistic fidelity in humans.

Research Support Resources

For researchers aiming to replicate or extend these findings, it can be valuable to modulate the gut microbiota or model antibiotic-induced dysbiosis. Agents such as Metronidazole (2-(2-methyl-5-nitroimidazol-1-yl)ethanol, SKU B1976) from APExBIO are frequently used for targeted inhibition of anaerobic bacteria and can support studies on microbiota-immune interactions or drug-drug interaction modulation. Its well-characterized activity as an OAT3 inhibitor and its suitability for research applications make it a practical tool for preclinical workflows involving both microbiota and immune endpoints. For detailed compound specifications, refer to the product information.